DNA damage repair gene defects combined predict the efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: a retrospective cohort study
Background Immune checkpoint inhibitors (ICIs) yield heterogeneous benefit in metastatic castration-resistant prostate cancer (mCRPC), underscoring the unmet need for robust predictive biomarkers. DNA damage repair (DDR) gene defects encompass mechanistically distinct subtypes—homologous recombination repair (HRR) defi...